Eph receptors and ephrins as targets for cancer therapy.

Eph receptors and ephrins as targets for cancer therapy.
复制标题

Eph 受体和肝配蛋白作为癌症治疗的靶点

DOI:
10.1111/j.1582-4934.2012.01612.x
复制
发表时间:
2012-12
影响因子:
5.3
通讯作者:
Chen L
Chen L
中科院分区:
医学2区
文献类型:
--
作者:
Xi HQ;Wu XS;Wei B;Chen L

文献摘要

参考文献

被引文献

相似文献

Eph受体酪氨酸激酶及其ephrin配体参与多种信号通路,并介导多种生理和病理过程的关键步骤。越来越多的实验证据表明,Eph受体和ephrin配体在许多人类肿瘤中过度表达,且与肿瘤生长、侵袭和转移相关。在这方面,Eph/ephrin系统为针对表达Eph的肿瘤的抗癌治疗提供了潜在令人兴奋的新靶点的基础。本综述的目的是概述Eph受体和ephrin配体在癌症中作用的当前进展,并讨论抗癌治疗的新治疗方法。
Eph receptor tyrosine kinases and their ephrin ligands are involved in various signalling pathways and mediate critical steps of a wide variety of physiological and pathological processes. Increasing experimental evidence demonstrates that both Eph receptor and ephrin ligands are overexpressed in a number of human tumours, and are associated with tumour growth, invasiveness and metastasis. In this regard, the Eph/ephrin system provides the foundation for potentially exciting new targets for anticancer therapies for Eph‐expressing tumours. The purpose of this review is to outline current advances in the role of Eph receptors and ephrin ligands in cancer, and to discuss novel therapeutic approaches of anticancer therapies.
DOI: 10.1016/j.cell.2012.01.024
发表时间: 2012-02-03
期刊: Cell
影响因子: 64.5
作者:
Bonanomi D;Chivatakarn O;Bai G;Abdesselem H;Lettieri K;Marquardt T;Pierchala BA;Pfaff SL
通讯作者: Pfaff SL
DOI: 10.1016/j.bmcl.2008.09.087
发表时间: 2008-11-01
影响因子: 2.7
作者:
Bardelle, Catherine;Coleman, Tanya;Williams, Emma J.
通讯作者: Williams, Emma J.
DOI: 10.1007/s00259-007-0503-5
发表时间: 2007-12-01
影响因子: 9.1
作者:
Cai, Weibo;Ebrahimnejad, Alireza;Chen, Xiaoyuan
通讯作者: Chen, Xiaoyuan
DOI: 10.1016/s0896-6273(00)80706-0
发表时间: 1999-03-01
期刊: NEURON
影响因子: 16.2
作者:
Brückner, K;Labrador, JP;Klein, R
通讯作者: Klein, R
DOI: 10.1126/science.275.5306.1640
发表时间: 1997-03-14
期刊: SCIENCE
影响因子: 56.9
作者:
Bruckner, K;Pasquale, EB;Klein, R
通讯作者: Klein, R